The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period

Access this Article

Search this Article

Author(s)

    • Kawai Hidetsugu
    • Department of Hematology, Isehara Cooperative Hospital, Japan|Department of Hematology/Oncology, Tokai University School of Medicine, Japan
    • Matsushita Hiromichi
    • Department of Laboratory Medicine, Tokai University School of Medicine, Japan|Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
    • Kawada Hiroshi
    • Department of Hematology/Oncology, Tokai University School of Medicine, Japan
    • Ogawa Yoshiaki
    • Department of Hematology/Oncology, Tokai University School of Medicine, Japan
    • Ando Kiyoshi
    • Department of Hematology/Oncology, Tokai University School of Medicine, Japan

Abstract

<p>Antithrombin (AT) deficiency, a rare disorder of the coagulation system, is a serious risk factor for thromboembolism. Approximately 50-90% of patients with AT deficiency develop thromboembolism during their lifetime. In addition, surgery is a major risk factor for thromboembolism in these patients. We herein report the case of a 90-year-old woman with AT deficiency who was safely and successfully managed using rivaroxaban (a direct oral factor Xa inhibitor) during the perioperative period of surgery for right femur fracture. The present case illustrates the effectiveness of rivaroxaban in preventing thromboembolisms due to surgery, even in very elderly patients with antithrombin deficiency. Further investigations are needed to determine the optimal dosage of rivaroxaban. </p>

Journal

  • Internal Medicine

    Internal Medicine 56(17), 2339-2342, 2017

    The Japanese Society of Internal Medicine

Codes

Page Top